Epiomic Epidemiology Series: Transient Ischaemic Attack Forecast in 8 Major Markets 2016-2026

February 2016 | 40 pages | ID: E1611E988D6EN
Black Swan Analysis limited

Abstracts

Transient ischaemic attack (TIA), also known as a mini or minor stroke, is an acute episode that results in a temporary loss of neurologic function. Similar to strokes, they are caused by the disruption of cerebral blood flow which can happen as a result of either partial or total occlusion or stenosis of a vessel. Unlike a stroke the symptoms of a TIA can resolve themselves usually between a few minutes and 24 hours.

This report provides the current incident population for TIA disease across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of TIA have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for TIA include:

• Atherosclerosis
• Coronary artery disease
• Aortic arch atheroma
• Atrial fibrillation
• Dyslipidaemias
• Diabetes
• Ischaemic heart disease
• Neurological conditions
• E.g. paresis, aphasia

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global TIA’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the incidence of the subdivided types of TIA and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on TIA’s incident population.
• Identify sub-populations within TIA which require treatment.
• Gain an understanding of the specific markets that have the largest number of TIA patients.

Contents

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Co-morbid Conditions/Features Associated with the Disease
Methodology for Quantification of Patient Numbers
Top-Line Incidence for Transient Ischaemic Attack
Features of TIA Patients
  Aetiology and Classification of TIA
  Vascular Territory and Stenosis of TIA
  Cardiac Conditions Associated with TIA
  Neurological Conditions of TIA
Abbreviations used in the Report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

List Of Tables

LIST OF TABLES & FIGURES

ABCD2 Risk Stratification Scores for Stroke
Incidence of TIA, total (000s)
Incidence of TIA, males (000s)
Incidence of TIA, females (000s)
Dichotomised risk factors in TIA patients, total (000s)
Aetiology of TIA in patients, total (000s)
Vascular territory in TIA patients, total (000s)
≥50% stenosis in vertebrobasilar TIA patients, total (000s)
≥50% stenosis in carotid TIA patients, total (000s)
Aortic arch atheroma (AAA) in TIA patients, total (000s)
AAA severity in TIA patients, total (000s)
Hypertension in TIA patients, total (000s)
Ischaemic heart disease in TIA patients, total (000s)
Atrial fibrillation in TIA patients, total (000s)
Clinical neurological symptoms in TIA patients, total (000s)
Unilateral paresis in TIA patients with neurological conditions, total (000s)
Dysarthia in TIA patients with neurological conditions, total (000s)
Unilateral sensory loss in TIA patients with neurological conditions, total (000s)
Aphasia in TIA patients with neurological conditions, total (000s)
Abbreviations and acronyms used in the Report
USA Incidence of TIA by 5-yr age cohort, males (000s)
USA Incidence of TIA by 5-yr age cohort, females (000s)
France Incidence of TIA by 5-yr age cohort, males (000s)
France Incidence of TIA by 5-yr age cohort, females (000s)
Germany Incidence of TIA by 5-yr age cohort, males (000s)
Germany Incidence of TIA by 5-yr age cohort, females (000s)
Italy Incidence of TIA by 5-yr age cohort, males (000s)
Italy Incidence of TIA by 5-yr age cohort, females (000s)
Spain Incidence of TIA by 5-yr age cohort, males (000s)
Spain Incidence of TIA by 5-yr age cohort, females (000s)
United Kingdom Incidence of TIA by 5-yr age cohort, males (000s)
United Kingdom Incidence of TIA by 5-yr age cohort, females (000s)
Brazil Incidence of TIA by 5-yr age cohort, males (000s)
Brazil Incidence of TIA by 5-yr age cohort, females (000s)
Japan Incidence of TIA by 5-yr age cohort, males (000s)
Japan Incidence of TIA by 5-yr age cohort, females (000s)